Grant: Undergraduate Student Research Awards (USRA)
University of Toronto
$6,000.00
The role of the kynurenine pathway in epileptogenesis
FY 2024-25
Summary
Epilepsy affects one percent of the population worldwide. The kynurenine pathway (KP) of tryptophan
metabolism is upregulated in both patients with epilepsy and in preclinical models. Knockout of the enzyme
indoleamine 2,3-dioxygenase (IDO), which is responsible for initiating the first step in the KP, has a beneficial
effect in mouse models of seizures and epilepsy. It is unknown whether pharmacological manipulation of IDO1
might have similar effects.
Hypothesis: Pharmacological IDO1 inhibition will decrease the development of epilepsy in a mouse kindling
model.
Methods: Young adult male and female mice will undergo kindling with the chemical convulsant
pentylenetetrazole (PTZ) while receiving either 1) oral treatment with the IDO1 inhibitor PF-0684002 (100
mg/kg daily) or 2) oral vehicle. All mice will be injected every other day with a low dose of PTZ until they
achieve a fully kindled state. We expect mice treated with IDO1 inhibitor will have a slower kindling rate,
requiring a greater number of injections to reach the kindled state.
Significance: This work will inform about the role of IDO1 and the KP in the development of epilepsy.
Pharmacological KP inhibition may represent a potential new treatment strategy for patients with epilepsy
Department
Program
Undergraduate Student Research Awards (USRA)
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
506765
Name
Mohamed Adam H
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The role of the kynurenine pathway in epileptogenesis
Programtype2
Miscellaneous Programs
Orgnameinp2
University of Toronto
Cihramount2
$6,000
Cihrequipment2
$0
Programname2
Undergraduate Student Research Awards (USRA)
Keyworddelim
Epilepsy; Epileptogenesis; Kynurenine Pathway; Tryptophan
Abstract
Epilepsy affects one percent of the population worldwide. The kynurenine pathway (KP) of tryptophan
metabolism is upregulated in both patients with epilepsy and in preclinical models. Knockout of the enzyme
indoleamine 2,3-dioxygenase (IDO), which is responsible for initiating the first step in the KP, has a beneficial
effect in mouse models of seizures and epilepsy. It is unknown whether pharmacological manipulation of IDO1
might have similar effects.
Hypothesis: Pharmacological IDO1 inhibition will decrease the development of epilepsy in a mouse kindling
model.
Methods: Young adult male and female mice will undergo kindling with the chemical convulsant
pentylenetetrazole (PTZ) while receiving either 1) oral treatment with the IDO1 inhibitor PF-0684002 (100
mg/kg daily) or 2) oral vehicle. All mice will be injected every other day with a low dose of PTZ until they
achieve a fully kindled state. We expect mice treated with IDO1 inhibitor will have a slower kindling rate,
requiring a greater number of injections to reach the kindled state.
Significance: This work will inform about the role of IDO1 and the KP in the development of epilepsy.
Pharmacological KP inhibition may represent a potential new treatment strategy for patients with epilepsy
Competitiondate
202405
Approvedterm2
0 yr 6 mths
Pinamesdelim
Mohamed, Adam H
Approvedterm
0 an 6 mois
Cihrcontribution2
~ $6,000~ $0~